Edition:
United Kingdom

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

14.68USD
23 Feb 2018
Change (% chg)

$-0.15 (-1.01%)
Prev Close
$14.83
Open
$14.96
Day's High
$15.00
Day's Low
$14.50
Volume
265,044
Avg. Vol
426,454
52-wk High
$19.94
52-wk Low
$13.00

Select another date:

Thu, Feb 15 2018

BRIEF-Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

* EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​ Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce

* SAYS ‍COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT​

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

Select another date: